Endocrine Abstracts

Introduction: Immune checkpoint inhibitors (ICIs) are an effective treatment for advanced cancer, but they are not free from immune-related adverse events (irAEs). A common irAES is thyroid dysfunction (TD-irAEs) and, as such, may influence patient survival and response to ICIs.Objetives: The aim was to determine the incidence and characteristics of TD-irAEs among patients with advanced cancer treated with ICIs in a real-life setting and to investigate t...